MedTrace Logo

Darusentan Effect on PET Uptake Heterogeneity

NCT00738049 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-08-15

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to test the hypothesis that myocardial perfusion heterogeneity, quantified by Markovian Homogeneity analysis of cardiac PET perfusion images, will improve in a quantitative manner after treatment with selective ETA receptor antagonist darusentan 100 mg per day for 2 weeks compared to baseline and post-treatment PET scans in clinically stable subjects with coronary atherosclerosis and/or risk factors.

Conditions

Interventions

DRUG

darusentan 100 mg

All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.

Sponsors & Collaborators

Principal Investigators

  • K Lance Gould, MD · University of Texas Medical School at Houston

  • Nils Johnson, MD · University of Texas Medical School at Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00738049 on ClinicalTrials.gov